Naslov
The clinical use of bone morphogenetic proteins (BMPs) revisited: A novel BMP6 biocompatible carrier device OSTEOGROW for bone healing

Autori
Vukičević, Slobodan ; Oppermann, Hermann ; Verbanac, Donatella ; Jankolija, Morana ; Popek, Irena ; Curak, Jasna ; Brkljačić, Jelena ; Pauk, Martina ; Erjavec, Igor ; Francetić, Igor ; Dumić-Čule, Ivo ; Jelić, Mislav ; Đurđević, Dragan ; Vlahović, Tomislav ; Novak, Ruđer ; Kufner, Vera ; Bordukalo Nikšić, Tatjana ; Kozlović, Marija ; Banić Tomišić, Zrinka ; Bubić-Špoljar, Jadranka ; Bastalić, Ivančica ; Vikić-Topić, Smiljka ; Perić, Mihaela ; Pećina, Marko ; Grgurević, Lovorka

Izvornik
International orthopaedics (0341-2695) 38 (2014), 3; 635-647

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
bone regeneration; bone morphogenetic protein 6; BMP6; bone fracture; OSTEOGROW; whole blood containing device; BMP2; BMP7; commercial bone devices

Sažetak
The purpose of this study was to revise the clinical use of commercial BMP2 (Infuse) and BMP7 (Osigraft) based bone devices and explore the mechanism of action and efficacy of low BMP6 doses in a novel whole blood biocompatible device OSTEOGROW. Complications from the clinical use of BMP2 and BMP7 have been systemically reviewed in light of their role in bone remodeling. BMP6 function has been assessed in Bmp6-/- mice by μCT and skeletal histology, and has also been examined in mesenchymal stem cells (MSC), hematopoietic stem cells (HSC) and osteoclasts. Safety and efficacy of OSTEOGROW have been assessed in rats and rabbits. Clinical use issues of BMP2 and BMP7 have been ascribed to the limited understanding of their role in bone remodeling at the time of device development for clinical trials. BMP2 and BMP7 in bone devices significantly promote bone resorption leading to osteolysis at the endosteal surfaces, while in parallel stimulating exuberant bone formation in surrounding tissues. Unbound BMP2 and BMP7 in bone devices precipitate on the bovine collagen and cause inflammation and swelling. OSTEOGROW required small amounts of BMP6, applied in a biocompatible blood coagulum carrier, for stimulating differentiation of MSCs and accelerated healing of critical size bone defects in animals, without bone resorption and inflammation. BMP6 decreased the number of osteoclasts derived from HSC, while BMP2 and BMP7 increased their number. Current issues and challenges with commercial bone devices may be resolved by using novel BMP6 biocompatible device OSTEOGROW, which will be clinically tested in metaphyseal bone fractures, compartments where BMP2 and BMP7 have not been effective.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti

POVEZANOST RADA